R
Robert S. Fulton
Researcher at Washington University in St. Louis
Publications - 254
Citations - 167513
Robert S. Fulton is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Genome & Gene. The author has an hindex of 109, co-authored 230 publications receiving 143530 citations. Previous affiliations of Robert S. Fulton include University of Washington & Brown University.
Papers
More filters
Journal ArticleDOI
The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia.
Meagan A. Jacoby,R E De Jesus Pizarro,Jin J Shao,Daniel C. Koboldt,Robert S. Fulton,G Zhou,R. Wilson,Matthew J. Walter +7 more
TL;DR: This study examined the DNA DSB response of primary bone marrow cells from t-AML patients and performed next-generation sequencing of 37 canonical homologous recombination and non-homologous end-joining DNA repair genes, and a subset of DNA damage response genes using tumor and paired normal DNA obtained from patients.
Journal ArticleDOI
The clonal evolution of metastatic colorectal cancer.
Ha X. Dang,Bradley A. Krasnick,Bradley A. Krasnick,Brian S. White,Julie G. Grossman,Julie G. Grossman,Matthew S. Strand,Matthew S. Strand,Jin Zhang,Christopher R. Cabanski,Christopher A. Miller,Robert S. Fulton,S. Peter Goedegebuure,S. Peter Goedegebuure,Catrina Fronick,Malachi Griffith,David E. Larson,Brian D. Goetz,Jason Walker,William G. Hawkins,William G. Hawkins,Steven M. Strasberg,Steven M. Strasberg,David C. Linehan,Kian H. Lim,A. Craig Lockhart,Elaine R. Mardis,Elaine R. Mardis,Richard K. Wilson,Richard K. Wilson,Timothy J. Ley,Christopher G. Maher,Ryan C. Fields,Ryan C. Fields +33 more
TL;DR: The observed intricate clonal heterogeneity and evolution affecting metastasis dissemination and PDX clonal selection suggest that single sample tumor sequencing and current PDX models may be insufficient to guide precision medicine.
Journal Article
North Carolina macular dystrophy (MCDR1) caused by a novel tandem duplication of the PRDM13 gene.
Sara J. Bowne,Lori S. Sullivan,Dianna K. Wheaton,Kirsten G. Locke,Kaylie D. Jones,Daniel C. Koboldt,Robert S. Fulton,Richard K. Wilson,Susan H. Blanton,David G. Birch,Stephen P. Daiger +10 more
TL;DR: The duplication found in the RFS355 family is distinct from the previously reported duplication and provides additional support that dysregulation of PRDM13, not CCNC, is the cause of NCMD mapped to the MCDR1 locus.
Journal ArticleDOI
Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer
Daniel Cui Zhou,Reyka G Jayasinghe,Siqi Chen,John M. Herndon,Michael D. Iglesia,Pooja Navale,Michael C. Wendl,Wagma Caravan,Kazuhito Sato,Erik Storrs,Chia-Kuei Mo,Jing Liu,Austin N. Southard-Smith,Yige Wu,Nataly Naser Al Deen,John M. Baer,Robert S. Fulton,Matthew A. Wyczalkowski,Ruiyang Liu,Catrina Fronick,Lucinda Fulton,Andrew Glen Shinkle,Lisa Thammavong,Houxiang Zhu,Hua Sun,Liang-Bo Wang,Yize Li,Chong Zuo,Joshua F. McMichael,Sherri R. Davies,Elizabeth L. Appelbaum,Keenan J. Robbins,Sara E. Chasnoff,Xiaolu Yang,Ashley N. Reeb,Clara Oh,Mamatha Serasanambati,Preet Lal,Rajees Varghese,J. Mashl,Jennifer Ponce,Nadezhda V. Terekhanova,Lina Yao,Fang Wang,Lijun Chen,Michael Schnaubelt,Rita Jui-Hsien Lu,Julie K. Schwarz,Sidharth V. Puram,Albert H. Kim,Sheng-Kwei Song,Kooresh I. Shoghi,Ken S. Lau,Tao Ju,Kenneth S. Chen,Deyali Chatterjee,William G. Hawkins,Hui Zhang,Samuel Achilefu,Milan G. Chheda,Stephen T. Oh,William E. Gillanders,Feng Chen,David G. DeNardo,R. C. Field,Li Ding +65 more
TL;DR: In this article , the authors studied 83 spatial samples from 31 patients (11 treatment-naïve and 20 treated) using single-cell/nucleus RNA sequencing, bulk-proteogenomics, spatial transcriptomics and cellular imaging.
Journal ArticleDOI
Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
Andrew L. Lin,Andrew L. Lin,Michael White,Michelle M. Miller-Thomas,Robert S. Fulton,Christina Tsien,Keith M. Rich,Robert E. Schmidt,David Tran,David Tran,Sonika Dahiya +10 more
TL;DR: Early contrast enhancement that develops during the first 6 months after chemoradiotherapy is typically due to PsP and occurs primarily in OG and MOA that are 1p/19q intact and IDH WT.